When tested in a head-to-head study, the drugs using pad technology beat the same ingredients in a suspension form.
For molluscum contagiosum, Dr. Rosen expressed his interest in a new 0.7% cantharidin product that has recently been FDA approved.
“It's in a precise applicator with a dye so you know which lesions you've treated, and which you haven't,” he says. “It's done once every 21 days, up to a maximum of four times and lesion clearance was quite good. Sixty-three percent to 83% of lesions in general disappeared. But even better if you looked at important sites like the head and neck, the face, the groin, the genitalia, you had over 80% completely clear by day 84.”
Highlighting one self-professed ‘oddball new drug,’ Dr. Rosen touched on the IV formulation of cetirizine for the treatment of acute urticaria.
“It’s a single dose every 24 hours and approved all the way down to six months of age,” he says. “Mostly it'll be used for adults and adolescence, but clearly a major advance in the treatment of bad urticaria because there are very few people have returned for any additional treatment.”